(Q51348266)

English

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

scientific article published on 25 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

phase II clinical trial

0 references

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

author name string

K Kaku

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

S Inoue

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

O Matsuoka

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

A Kiyosue

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

H Azuma

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

N Hayashi

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

T Tokudome

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

A M Langkilde

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

S Parikh

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

publication date

25 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

15

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

432-440

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

Islet beta cell failure in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

SGLT2 inhibition--a novel strategy for diabetes treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Improving efficiency of inferences in randomized clinical trials using auxiliary covariates

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12047

21 January 2018

Identifiers

10.1111/DOM.12047

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/23194084

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51348266&oldid=1221872801"